Chugai
To see an up-to date selection of historical analyses and insights on
Chugai,
visit our
new, dynamically updated Company Summary report pages for Chugai.
As a Guest User, you will have FREE access to a selection of historical analyses
and insights from EvaluatePharma®.
How to access FREE content
- Search the content using the search box at the top of every page
- Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
- Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar
Register for FREE to access even more content including 2007
Product Sales and Rankings.
A small selected sample of reports and related news headlines for
Chugai are available below.
Free sample reports are also available for other Companies.
To find out how you can access more detailed information on
Chugai,
or on any other Company covered by EvaluatePharma® Contact Us today.
CONSENSUS FORECASTS ($US mln) - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
Annual Sales WW - Sales |
Growth per Year (%) |
|
|
Rank |
Product |
Generic Name |
Pharmacological Class |
2006 |
2007 |
2007 |
| Chugai |
1 |
Epogin/EPOCH |
epoetin beta |
Erythropoietin |
545 |
466 |
|
(15%) |
|
|
|
2 |
Neutrogin/Granocyte |
lenograstim |
Colony stimulating factor |
310 |
333 |
|
7% |
|
|
|
3 |
Sigmart |
nicorandil |
Potassium channel agonist |
155 |
152 |
|
(2%) |
|
|
|
|
|
Note: Shaded Cells |
|
|
|
|
PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
|
|
Rank |
Product |
Therapeutic Category |
Therapeutic Subcategory |
Pharmacological Class |
Phase (Current) |
| Chugai |
1 |
Mircera |
Blood |
Anti-anaemics |
Erythropoietin |
Phase III |
|
|
- |
AVS (Antevas) |
Cardiovascular |
Cerebral & peripheral vasotherapeutics |
Hydroxyl radical scavenger |
Filed |
|
|
- |
ED-71 |
Musculoskeletal |
Bone calcium regulators |
Vitamin D3 analogue |
Phase III |
|
|
|
FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers
|
| Chugai |
|
|
2005 |
2006 |
| Valuation Measures |
| Based on Latest Share Prices |
| Valuing the Equity |
| Market Capitalisation |
9,184 |
9,184 |
| PE Ratio (diluted) - Normalised (x) |
19.4 |
27.9 |
|
|
| Valuing the Enterprise |
| Enterprise Value |
7,825 |
7,825 |
| Free Cash Flow (Pre-Dividends) |
556 |
172 |
| FCF Yield (%) |
7.1% |
2.2% |
|
|
| Forecast Financials |
| Income Statement |
| Total Revenues |
2,975 |
2,804 |
| Cost of Goods Sold |
(1,086) |
(1,144) |
| S,G & A |
(714) |
(688) |
| R&D |
(455) |
(470) |
| Other Income/ Expense - Net |
24 |
17 |
| EBIT - Normalised |
744 |
518 |
| Net Interest & Financial Items |
3 |
15 |
| Pre-tax Profits - Normalised |
747 |
533 |
| Exceptionals |
37 |
8 |
| Income Before Taxes |
784 |
541 |
| Tax |
(284) |
(197) |
| Tax Rate (%) |
36.2% |
36.3% |
| Minorities |
(12) |
(14) |
| Net Income - Reported |
488 |
330 |
| Net Income - Normalised |
470 |
326 |
|
|
| Per Share Data |
| EPS - Diluted |
0.88 |
0.60 |
| EPS - Basic |
0.89 |
0.60 |
| EPS - Normalised (diluted) |
0.85 |
0.59 |
| EPS - Normalised (basic) |
0.85 |
0.59 |
| Avg. Shares Outstanding - Diluted |
554.7 |
554.8 |
| Avg. Shares Outstanding - Basic |
550.6 |
554.0 |
| DPS |
0.29 |
0.26 |
|
|
|
NEWS - Selected Product News Headlines (as of 11 June 2008)
|
| New Overall Survival Study Results Confirm Oral Xeloda® plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
|
(Roche)
|
13-Jan-2009 |
| Eldecalcitol, An Active Vitamin D3 Derivative, Reduces Incidence of New Vertebral Fractures in Osteoporosis Patients in Phase III Clinical Trial
|
(Chugai)
|
16-Dec-2008 |
| Femara® First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
|
(Novartis)
|
11-Dec-2008 |
| Herceptin Given Prior to Surgery Improves the Chance of Survival Without Relapse for Women With HER2-Positive Breast Cancer
|
(Roche)
|
11-Dec-2008 |
| Update on FDA Registration of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody for Rheumatoid Arthritis
|
(Chugai)
|
04-Dec-2008 |
| Roche and FDA Agree on Pathway Towards U.S. Approval of Actemra (tocilizumab)
|
(Roche)
|
04-Dec-2008 |
| Approval of a New Indication for Oxarol® Ointment/Lotion (nonproprietary name: maxacalcitol), Psoriasis Vulgaris Treatment Topical Products Containing Active Vitamin D3, for Extended Treatment of Palmoplantar Pustulosis
|
(Chugai)
|
28-Nov-2008 |
| Anti-Malignancy Agent / anti-VEGF Humanised Monoclonal Antibody, Avastin® Application for Approval of Additional Indication of NSCLC
|
(Chugai)
|
26-Nov-2008 |
| RoACTEMRA®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Receives Positive Opinion in Europe for the Treatment of Rheumatoid Arthritis
|
(Chugai)
|
25-Nov-2008 |
| RoActemra Receives Positive Opinion in Europe for the Treatment of Rheumatoid Arthritis
|
(Roche)
|
21-Nov-2008 |
| Extension of the Shelf Life for the Anti-influenza Agent, Tamiflu® Capsule 75, for the Purpose of Stockpiling by the Japanese Government as a Measure against New Influenza
|
(Chugai)
|
12-Nov-2008 |
| Data from Overseas Phase III Trial (LITHE) of "Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Demonstrates Efficacy in Preventing Structural Joint Damage
|
(Chugai)
|
27-Oct-2008 |
| New Data Shows ACTEMRA Inhibits Progression of Joint Destruction and Improves Physical Function of Patients With Rheumatoid Arthritis
|
(Roche)
|
27-Oct-2008 |
| Phase III Study Showed Rituxan in Combination With Chemotherapy Improved Progression-free Survival in Patients With Relapsed Chronic Lymphocytic Leukemia
|
(Biogen Idec)
|
06-Oct-2008 |
| Actemra delayed in US but confidence remains high
|
(Roche)
|
19-Sep-2008 |
| FDA Issues Complete Response Letter to Roche for Actemra Biologics License Application
|
(Roche)
|
18-Sep-2008 |
| Avastin: Only Biologic to Demonstrate Significant Survival Benefit in First-Line and Second-line Metastatic Colorectal Cancer Patients
|
(Roche)
|
16-Sep-2008 |
| FDA Advisory Committee Votes in Favor to Recommend Approval of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, for Rheumatoid Arthritis
|
(Chugai)
|
30-Jul-2008 |
| Backing of Actemra significantly justifies Roche's Chugai move
|
(Roche)
|
30-Jul-2008 |
| FDA Advisory Committee Recommends Approval of ACTEMRA® (tocilizumab) for the Treatment of Rheumatoid Arthritis
|
(Roche)
|
29-Jul-2008 |
| Data from Overseas Phase III Trial (RADIATE and AMBITION) Demonstrates Efficacy of "Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, in Rheumatoid Arthritis Patients
|
(Chugai)
|
16-Jun-2008 |
| New Data Reveals Actemra is the First and Only Biologic Drug to Show Superiority Over Current Standard of Care in Rheumatoid Arthritis
|
(Roche)
|
13-Jun-2008 |
| ACTEMRA® (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
|
(Roche)
|
13-Jun-2008 |
| CellCept® and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus A Standard-Dose CNI
|
(Roche)
|
04-Jun-2008 |
| Final Results of the CellCept® Spare the Nephron (STN) Study Shows Maintenance Therapy Is Associated with Improved Renal Function
|
(Roche)
|
02-Jun-2008 |
| Pertuzumab With Herceptin Shows Impressive Results in Women With Advanced HER2-Positive Breast Cancer
|
(Roche)
|
30-May-2008 |
| Actemra Inhibits Joint Damage and Improves Physical Function of Patients With Rheumatoid Arthritis
|
(Roche)
|
09-May-2008 |
| Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C
|
(Roche)
|
28-Apr-2008 |
| Actemra Approved in Japan to Treat Patients With Rheumatoid Arthritis
|
(Roche)
|
16-Apr-2008 |
| Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody Obtained Approval for Indications of Rheumatoid Arthritis, Polyarticular-Course Juvenile Idiopathic Arthritis and Systemic-Onset Juvenile Idiopathic Arthritis
|
(Chugai)
|
16-Apr-2008 |
| OSI Pharmaceuticals Summarizes Data Presented at the Annual Meeting of the American Association for Cancer Research
|
(OSI Pharmaceuticals)
|
16-Apr-2008 |
| International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
|
(Roche)
|
20-Mar-2008 |
| Femara® Helps Protect Against Return of Breast Cancer Even When Treatment Starts Several Years After Completing Tamoxifen Therapy
|
(Novartis)
|
10-Mar-2008 |
| Combination Therapy of Anti-cancer Agents, Xeloda®, Elplat® and Avastin®, and Monotherapy of Xeloda® Filed for Advanced or Recurrent Colorectal Cancer
|
(Chugai)
|
29-Feb-2008 |
| Herceptin Approved in Japan for Early Treatment in Patients with HER2-Positive Breast Cancer
|
(Roche)
|
29-Feb-2008 |
| Anti-Cancer Agent Herceptin® Obtained Approval for a New Indication for Adjuvant Therapy in Breast Cancer that Overexpresses HER2
|
(Chugai)
|
29-Feb-2008 |
|
|
|
IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
|
|
|
|
|
Product |
Generic Name |
| Chugai |
Acetanol |
acebutolol |
|
|
Actemra |
tocilizumab |
|
|
Adcon-L |
carbohydrate polymer gel |
|
|
Adcon-T/N |
carbohydrate polymer gel |
|
|
AHM |
- |
|
|
Alfarol |
alfacalcidol |
|
|
Amoban |
zopiclone |
|
|
AN-132 |
- |
|
|
Avastin |
bevacizumab |
|
|
AVS (Antevas) |
nicaraven |
|
|
Benambax |
pentamidine isetionate |
|
|
Blutal |
chondroitin sulfate iron colloid |
|
|
BO-653 |
- |
|
|
Bonviva |
ibandronate |
|
|
CAL |
- |
|
|
Cefotax |
cefotaxime |
|
|
CellCept |
mycophenolate mofetil |
|
|
CHS13340 |
parathyroid hormone |
|
|
CIF (R7167) |
- |
|
|
Copegus |
ribavirin |
|
|
CSG452 |
- |
|
|
ED-71 |
eldecalcitol |
|
|
Epogin/EPOCH |
epoetin beta |
|
|
Euglucon |
glyburide |
|
|
Evista |
raloxifene |
|
|
Femara |
letrozole |
|
|
Fortovase/Invirase |
saquinavir mesylate |
|
|
Furtulon |
doxifluridine |
|
|
GC33 |
- |
|
|
Glyceol |
glycerol |
|
|
GM-611 |
mitemcinal fumarate |
|
|
Herceptin |
trastuzumab |
|
|
IC-351 |
tadalafil |
|
|
Inhibace |
cilazapril |
|
|
ITM-077 |
taspoglutide |
|
|
Keiten |
cefpirome |
|
|
Kytril |
granisetron |
|
|
Lanirapid |
metildigoxin |
|
|
LY-139603 |
atomoxetine |
|
|
LY-335979 |
zosuquidar |
|
|
Menamin |
ketoprofen |
|
|
Mircera |
methoxy polyethylene glycol-epoetin beta |
|
|
MX-68 |
- |
|
|
NA808 |
- |
|
|
Natulan |
procarbazine |
|
|
Neutrogin/Granocyte |
lenograstim |
|
|
Omnitarg |
pertuzumab |
|
|
Optison/FS-69 |
- |
|
|
Oxarol |
maxacalcitol |
|
|
Oxarol Ointment/Oxarol Lotion |
maxacalcitol |
|
|
Pegasys |
peginterferon alfa-2a |
|
|
Pegasys & Copegus |
peginterferon alfa-2a & ribavirin |
|
|
Picibanil |
streptococcus pyogenes bacteria |
|
|
Pletaal |
cilostazol |
|
|
Preran |
trandolapril |
|
|
Prozac |
fluoxetine |
|
|
R1503 |
pamapimod |
|
|
R1579 |
carmegliptin |
|
|
R1594 |
ocrelizumab |
|
|
R1678 |
- |
|
|
R450 (alpha-1 agonist) |
dabuzalgron |
|
|
R483 (insulin sensitiser) |
edaglitazone |
|
|
R7159 |
afutuzumab |
|
|
Renagel |
sevelamer |
|
|
Rituxan |
rituximab |
|
|
Rocephin |
ceftriaxone |
|
|
Rohypnol |
flunitrazepam |
|
|
Rythmodan |
disopyramide |
|
|
Sigmart |
nicorandil |
|
|
Suvenyl |
sodium hyaluronate |
|
|
TA-270 |
- |
|
|
Tamiflu |
oseltamivir |
|
|
Tarceva |
erlotinib |
|
|
Taxotere |
docetaxel |
|
|
TP300 |
- |
|
|
TPO Agonist Minibody |
- |
|
|
Ulcerlmin |
sucralfate |
|
|
VAL |
valine |
|
|
Vesanoid |
tretinoin |
|
|
Xeloda |
capecitabine |
|
|
Xenical |
orlistat |
|
|
Xyotax |
paclitaxel poliglumex |
|
|
Zenol |
felbinac & menthol |
|
|
|
EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx
(prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings,
annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts
for marketed and emerging products are built-up using recent research reports from top equity analysts.
Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I,
phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy,
patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates,
deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age -
plus many more data items and analytics unique to EvaluatePharma®.
Aggregations of these measures at a high-level means that companies may be ranked against each other on items
such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs
organic sales), sales by therapy area or technology and various other concentration measures. These
aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.
Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available
Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.
